CRC Research Update — May 25, 2026
Today's colorectal cancer research highlights
The CRC Digest
Curated CRC research — accessible, accurate, actionable
Monday, May 25, 2026
2 min readIMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.
CRC Research Update
-
Circulating tumor DNA predicts recurrence risk in stage III colorectal cancer
A systematic review and meta-analysis examines the prognostic value of circulating tumor DNA for recurrence risk in stage III colorectal cancer. (Clinical Colorectal Cancer)
-
Watch-and-wait versus surgery: quality of life compared in rectal cancer survivors
A study compared quality of life outcomes between rectal cancer patients managed with watch-and-wait versus those who underwent surgery. (Clinical Colorectal Cancer)
-
Maintenance therapy with anti-EGFR shows different side effect patterns than stop-and-go approach
A pooled analysis of three phase II trials in left-sided, RAS/BRAF wild-type metastatic colorectal cancer compared toxicity over time for patients receiving maintenance therapy with anti-EGFR drugs versus intermittent treatment breaks. (Journal of the National Cancer Institute)
-
Experimental nanomedicine targets KRAS G12D mutation in metastatic colorectal cancer
Preclinical research describes a macrophage-hitchhiking delivery system combining gemcitabine and a KRAS G12D inhibitor that improved drug delivery to lung metastases and triggered immune responses in colorectal cancer models. (Journal of Controlled Release)
Research continues to refine how we detect, treat, and monitor colorectal cancer — bringing more personalized approaches to care.
The CRC Digest
Research intelligence for the colorectal cancer community
Get CRC research intelligence delivered weekly — free.
SubscribeBrowse by Topic
Not Medical Advice
The CRC Digest provides research summaries for informational and educational purposes only. This is not medical advice. Always consult your healthcare provider before making any decisions about your care.
Content is curated with AI assistance and reviewed by the editorial team.